Trials / Conditions / Growth Hormone Deficiency in Children

Growth Hormone Deficiency in Children

24 registered clinical trials studyying Growth Hormone Deficiency in Children — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency NCT07126288	Shenzhen Kexing Pharmaceutical Co., Ltd.	Phase 2 / Phase 3
Enrolling By Invitation	Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hor NCT06109935	Novo Nordisk A/S	—
Completed	A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week NCT04970654	Novo Nordisk A/S	Phase 3
Enrolling By Invitation	Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With NCT03972345	Novo Nordisk A/S	—
Completed	A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compare NCT03811535	Novo Nordisk A/S	Phase 3
Completed	Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy NCT03672617	Novo Nordisk A/S	—
Completed	Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan NCT03212131	Novo Nordisk A/S	Phase 1
Completed	Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan NCT03186495	Novo Nordisk A/S	Phase 1
Completed	Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treat NCT02616562	Novo Nordisk A/S	Phase 2
Completed	Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of NCT02580032	Novo Nordisk A/S	—
Completed	A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-act NCT01973244	Novo Nordisk A/S	Phase 1
Completed	First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects NCT01514500	Novo Nordisk A/S	Phase 1
Completed	Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated NCT01327924	Novo Nordisk A/S	—
Completed	Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents NCT01245374	Novo Nordisk A/S	Phase 4
Withdrawn	An Observational Study on Treatment Compliance by Children Treated With Growth Hormone NCT01068639	Novo Nordisk A/S	—
Completed	A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacody NCT00936403	Novo Nordisk A/S	Phase 2
Completed	Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™ NCT01500486	Novo Nordisk A/S	—
Completed	Observational Prospective Study on Patients Treated With Norditropin® NCT00960128	Novo Nordisk A/S	—
Completed	Non-interventional Study of Patients Using Norditropin® for Growth Hormone Deficiency or Turner Syndrome NCT01604161	Novo Nordisk A/S	—
Completed	Liquid Somatropin Formulation in Children With Growth Hormone Deficiency NCT00567385	Novo Nordisk A/S	Phase 4
Completed	Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency NCT01502124	Novo Nordisk A/S	Phase 3
Completed	Safety and Efficacy of Long-term Somatropin Treatment in Children NCT01543867	Novo Nordisk A/S	—
Completed	Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency NCT01563926	Novo Nordisk A/S	Phase 3
Completed	Effect of Growth Hormone in Children With Growth Hormone Deficiency NCT00262249	Novo Nordisk A/S	Phase 3